Specialty Pharmacy

Study finds a common assortment of reasons for non-initiation of hepatitis C therapy, regardless of patient race or ethnicity.

Majority of errors classified as incomplete, inaccurate, and omitted in various databases of pharmaceutical products.

Researchers find inaccuracies in ODIC drug summaries.

Macrophages found to be a clear source of replicating HIV.

Nanoparticles selectively target tumor vessels or cancerous cells.

Patients often leave the hospital on different and more complicated drug therapies.

Disabled Medicare beneficiaries, especially those with multiple comorbidities, struggle to afford their prescriptions.

Disabled Medicare beneficiaries, especially those with many comorbidities, continue to struggle to afford prescriptions.

Significant correlation found between physicians who accept industry money from pharmaceutical or medical device companies and brand name prescribing rates.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Genetic and molecular specialized testing may improve targeted therapy for skin cancer.

Cellular protein helps HIV remain undetected.

Signs of multiple sclerosis may be found via magnetic resonance imaging scanners in the near future.

New generation of oncology drugs could improve treatment for patients with therapy-resistant cancer.

Top stories of the week on Specialty Pharmacy Times.

Program can reduce the amount of drugs that go through the R&D pipeline and then fail in clinical trials due to side effects.

Recent advances and updates in oncology and cancer drug development.

The targeted multi-kinase inhibitor sorafenib is the standard of care for advanced HCC, but it has limited therapeutic benefit.

Aberrant protein mutation associated with the black plague may lead to treatments for HIV and hepatitis C.

Special interest legislation could inflate generic drug prices.

Subset of T cells can confer therapeutic immune responses.

Nanoparticles can change shape to gain entry into diseased tissue and reduce the toxic effects of chemotherapy.

Twitter can increase awareness and patient recruitment for clinical trials of cancer drugs.

Using PBM tools at current levels can save payers $654 billion over the next 10 years.

The high cost of HCV treatment remains a hurdle for patients, payers, and providers.

Nonmedical workers and mobile technology can play a pivotal role in risk prediction.

Histologic improvement greater with experimental drug versus placebo in patients with moderate-to-severe ulcerative colitis.

Individual genetic backdrop may be less important than previously thought in the development of multiple sclerosis.